跳至主要内容
临床试验/JPRN-UMIN000030680
JPRN-UMIN000030680已完成未知

Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by glecaprevir and pibrentasvir therapy in HCV-infected hemodialysis patients - Comprehensive analysis of iron and mineral-bone metabolism after HCV clearance by glecaprevir and pibrentasvir therapy in HCV-infected hemodialysis patients

Tokai University School of Medicine, Department of Gastroenterology and Hepatology0 个研究点目标入组 30 人开始时间: 2018年1月4日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients with decompensated cirrhosis 2)Patients complicated with hepatocellular carcinoma 3)Patients with HBs antigen or anti-HIV antibody positive 4)Patients with a history of hypersensitivity to lecaprevir and pibrentasvir 5)Patients receiving atazanavir sulfate (Reyataz), atorvastatin calcium hydrate (Lipitor etc.), rifampicin (Rifazine etc.) 6)Other patients whom the chief investigator or a sub-investigators considers inappropriate

研究者

发起方
Tokai University School of Medicine, Department of Gastroenterology and Hepatology

相似试验